Chids Mahadevan Form 4 Applied Therapeutics / Chids Mahadevan ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mahadevan Chids

(Last) (First) (Middle)

C/O APPLIED THERAPEUTICS, INC.

545 FIFTH AVENUE, SUITE 1400

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Applied Therapeutics Inc. [ APLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/02/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$2.02	08/02/2022		D(1)			19,058	(2)	04/13/2032	Common Stock	19,058	(1)	0	D
Employee Stock Option (Right to Buy)	$1.05	08/02/2022		D(1)		19,058		(2)	04/13/2032	Common Stock	19,058	(1)	19,058	D
Employee Stock Option (Right to Buy)	$17.05	08/02/2022		D(1)			7,264	(3)	05/10/2031	Common Stock	7,264	(1)	0	D
Employee Stock Option (Right to Buy)	$1.05	08/02/2022		D(1)		7,264		(3)	05/10/2031	Common Stock	7,264	(1)	7,264	D
Employee Stock Option (Right to Buy)	$49.6	08/02/2022		D(1)			8,824	(4)	01/29/2030	Common Stock	8,824	(1)	0	D
Employee Stock Option (Right to Buy)	$1.05	08/02/2022		D(1)		8,824		(4)	01/29/2030	Common Stock	8,824	(1)	8,824	D

Explanation of Responses:

1. The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

2. Reflects an initial grant of 19,058 Options granted on April 13, 2022 that vests as follows: One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on April 13, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

3. Reflects an initial grant of 13,412 Options granted on May 10, 2021 that vests as follows: One-fourth (1/4th) of the shares subject to the Option were vested upon grant and the remainder of the shares subject to the Option shall vest thereafter in equal monthly installments over the three-year period following the date of grant, subject to the Reporting Person continuing to provide services through each such date.

4. Reflects an initial grant of 14,606 Options granted on January 29, 2020 that vests as follows: One-fourth (1/4) of the shares subject to the Option shall vest on January 30, 2021, and one thirty-sixth (1/36) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

Remarks:

Title: Senior Vice President of Finance (Interim Principal Financial Officer)

	/s/ Shoshana Shendelman, as attorney-in-fact	08/04/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.